• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Oncology

Inappropriate clinical management decisions are possible secondary to use of Bazett formula for QTc in context of chemotherapy cancer treatment

byKassandra McFarlaneandSze Wah Samuel Chan
October 3, 2022
in Cardiology, Chronic Disease, Oncology
Reading Time: 3 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. The Bazett formula showed greater CTCAE grading than either Fridericia or Framingham formulae in 40.9% of total ECGs.

2. In patients receiving QT-prolonging chemotherapy, 17.9% of clinical management changes were inappropriate based on the formula used.

Evidence Rating Level: 2 (Good)

Free ECG reference: QT interval and QTc calculator: Bazett, Fridericia, Framingham and Hodges side by side

Study Rundown: A common side effect of chemotherapy treatment for cancer includes prolonged QT interval, which can potentially lead to fatal arrhythmias. There are multiple formulae available to determine corrected QT (QTc) interval and no standardized approach to which formula is appropriate to inform clinical decisions. This study explored how clinical management decisions and adverse event (AE) grading of QTc prolongation are associated to QT interval formula. The Bazett, Fridericia, and Framingham formulae were compared. There was concordance among all 3 formulae when evaluating for Common Terminology Criteria for Adverse Events (CTCAE) grading of QTc prolongation in 56.6% of all ECGs, however, the use of the Bazett formula showed greater CTCAE grading than either Fridericia or Framingham formulae in 40.9% of total ECGs. There were 421 patients receiving chemotherapy treatment that prolongs the QT interval (2,340 ECGs collected). Generally, these patients had greater QTc values than the entire cohort. The Bazett formula identified grade 3 CTCAE toxicity in a greater percent of these ECGs than either the Fridericia or Framingham formulae. Out of 142 patients (496 ECGs) on QTc-prolonging treatment, there were 28 encounters resulting in a change in clinical management secondary to QT prolongation. Of these, 17.9% were inappropriate when considering the formula chosen. Of the 496 ECGs collected on these patients, only 30 had medical record documentation of the QTc formula selected to guide clinical management. Additional limitations to this study include inability to infer causality due to the retrospective nature of the study. Overall, the results from this study provide evidence that the use of the Bazett formula results in likely inappropriate treatment modifications for patients receiving QTc-prolonging chemotherapy as it calculates higher QTc values and almost triplicate indication of grade 3 CTCAE toxicity when compared with two other formulae.

Click to read the study in JAMA Oncology

RELATED REPORTS

The use of neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer may reduce mortality

Adjuvant chemotherapy not linked to improved outcomes in localized appendiceal adenocarcinoma

Relevant Reading: Trials and tribulations of corrected QT interval monitoring in oncology: rationale for a practice-changing standardized approach

In-Depth [prospective cohort]: This prospective cohort study was completed out of the University of North Carolina Cancer Hospital in the United States. The study was conducted on the electrocardiograms (ECGs) of 6,881 adult patients for a total of 19,955 ECGs collected over a 10-year period. Regarding the CTCAE criteria, there was 58.3% concordance between Bazett and Fridericia, 56.8% between Bazett and Framingham, and 94.2% between Framingham and Fridericia. 2.7% of ECGs were found to have grade 3 toxicity using Fridericia formula, 1.8% using Framingham, and 9.0% using Bazett formula. 1.8% of all ECGs were identified as Grade 3 by all three formulae. There was a median difference between Bazett and Fridericia on absolute QTc values of 26.4 milliseconds (ms) (95% confidence interval (CI), -9.3 to 62.0 ms). The median difference between Bazett and Framingham was 27.8 ms (95% CI, -13.1 to 71.7 ms) and 1.5 ms between Fridericia and Framingham (95% CI, -7.8 to 13.8 ms). Patients receiving chemotherapy known to prolong the QT had greater QTc values than the entire cohort, and the mean differences were 3.43ms by Framingham formula, 3.24ms by Fridericia, and 1.55ms by Bazett formula. Using all 3 formulae, 2.6% of these ECGs met grade 3 CTCAE criteria. When considering the formulae separately, grade 3 toxicity was identified in 2.7% (Framingham), 4.5% (Fridericia), and 12.5% (Bazett) of these ECGs. There were 293 ECGs from this cohort that met grade 3 CTCAE toxicity criteria using Bazett formula, but 65.2% of those were identified as grade 2 or less by Framingham or Fridericia formulae. Of 142 patients (496 ECGs) on QTc-prolonging treatment, there were 28 visits resulting in clinical changes secondary to QT prolongation. There were 5 clinical decisions that were determined to be inappropriate based on the QTc formula selection. Only 6% of encounters had the chosen QTc formula documented in the record.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: BazettchemotherapyQTc prolongation
Previous Post

Extended-interval dosing with pembrolizumab is similar to standard-interval dosing

Next Post

Differences in cancer implications for clinical care among CHEK2 variants

RelatedReports

A collage illustrating the urinary bladder, immune system elements, cancer cells, and an IV bag, highlighting immunotherapy for urothelial cancer.
Chronic Disease

The use of neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer may reduce mortality

September 22, 2026
An illustration featuring a large intestine surrounded by various silhouettes of heads, representing demographics, alongside abstract elements.
Chronic Disease

Adjuvant chemotherapy not linked to improved outcomes in localized appendiceal adenocarcinoma

September 18, 2026
Quick Take: Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening
Chronic Disease

Molecularly guided therapy may improve outcomes in patients with unfavourable cancer of unknown primary compared with standard chemotherapy

September 7, 2026
Heart failure collage: a smiling older woman in a turtleneck beside an engraved heart and a metal watering can
Weekly Rewinds

2 Minute Medicine Rewind September 7, 2026

September 7, 2026
Next Post
Reduced neuronal BRCA1 associated with decreased DNA repair in Alzheimer’s disease [PreClinical]

Differences in cancer implications for clinical care among CHEK2 variants

Rectal indomethacin dose escalation for prevention of pancreatitis after endoscopic retrograde cholangiopancreatography in high-risk patients

Bionic pancreas reduces glycated hemoglobin levels compared to semi-automated insulin-delivery systems

Acetazolamide increases rate of successful decongestion in patients with acute decompensated heart failure

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Long-term use of mometasone (Asmanex) in adults with sickle cell disease without formal diagnosis of asthma may worsen disease activity
  • Few patients had ED lumbar CT or MRI within 30 days after low-acuity back-pain radiography at urgent care centers
  • A 34-circular RNA blood signature predicted Alzheimer’s disease progression and improved prediction when combined with pTau217
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.